Suppr超能文献

贝伐单抗致大鼠肾损伤的机制

Mechanism of kidney injury caused by bevacizumab in rats.

作者信息

Zhao Ning, Xu Qunhong, Wang Ming, Fei Xiao, Pan Yuelong, Chen Xueqing, Ma Shenglin

机构信息

Department of Nephrology, Hangzhou First People's Hospital Hangzhou 310006, Zhejiang Province, China.

Department of Oncology, Hangzhou Cancer Hospital Hangzhou 310006, Zhejiang Province, China.

出版信息

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8675-83. eCollection 2014.

Abstract

OBJECTIVE

We investigate kidney injury caused by high dose bevacizumab to uncover the possible mechanisms involving in this process.

METHODS

Forty rats were divided into four groups: cisplation group (treated with 1 mg/kg cisplation), Bev-high group (treated with 5 mg/kg bevacizumab); Bev-low group (treated with 2.5 mg/kg bevacizumab) and control group (treated with saline). The urine microalbumin, serum cystatin C, blood urea nitrogen and serum creatinine were detected in the four group rats, respectively. The immunoglobulin of IgG, IgA and IgM and protein of VEGF (vascular endothelial growth factor) and nephrin were detected by immunohistochemical methods.

RESULTS

All the levels of microalbumin, cystatin C, serum creatinine and blood urea nitrogen in Bev-high group were significantly higher than those in normal control group (P < 0.05). The cystatin C was much more increased in kidney Bev-high group than cisplatin and Bev-low groups (P < 0.05). The light microscope showed a normal glomerular morphology in the four groups, while the electronic microscopy showed the podocytes were extensively fused in cisplatin group and Bev-high group. The two groups were found IgG and IgM deposition as well. The VEGF in kidney amples were down regulated in high dose bevacizumab group, whereas the nephrin and IgA showed no significant expression changes at all.

CONCLUSION

Bevacizumab increases the risk of injury in glomerular filtration barrier in a dose dependent model. The injury may not only associate with the rising level of proteinuria but also with podocyte-dependent membrane structures.

摘要

目的

我们研究高剂量贝伐单抗所致的肾损伤,以揭示此过程中可能涉及的机制。

方法

40只大鼠分为四组:顺铂组(用1mg/kg顺铂治疗);贝伐单抗高剂量组(用5mg/kg贝伐单抗治疗);贝伐单抗低剂量组(用2.5mg/kg贝伐单抗治疗)和对照组(用生理盐水治疗)。分别检测四组大鼠的尿微量白蛋白、血清胱抑素C、血尿素氮和血清肌酐。采用免疫组化方法检测IgG、IgA和IgM免疫球蛋白以及血管内皮生长因子(VEGF)和nephrin蛋白。

结果

贝伐单抗高剂量组的微量白蛋白、胱抑素C、血清肌酐和血尿素氮水平均显著高于正常对照组(P<0.05)。肾贝伐单抗高剂量组的胱抑素C升高幅度远大于顺铂组和贝伐单抗低剂量组(P<0.05)。光镜下四组肾小球形态正常,而电镜下顺铂组和贝伐单抗高剂量组足细胞广泛融合。两组还发现有IgG和IgM沉积。高剂量贝伐单抗组肾组织样本中的VEGF下调,而nephrin和IgA表达无明显变化。

结论

贝伐单抗在剂量依赖模型中增加了肾小球滤过屏障损伤的风险。这种损伤不仅可能与蛋白尿水平升高有关,还可能与足细胞依赖的膜结构有关。

相似文献

1
Mechanism of kidney injury caused by bevacizumab in rats.贝伐单抗致大鼠肾损伤的机制
Int J Clin Exp Pathol. 2014 Dec 1;7(12):8675-83. eCollection 2014.

引用本文的文献

4
Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury.顺铂诱导肾损伤中Nrf2的氧化还原调节
Antioxidants (Basel). 2023 Sep 6;12(9):1728. doi: 10.3390/antiox12091728.

本文引用的文献

5
Progress in pathogenesis of proteinuria.蛋白尿发病机制的研究进展
Int J Nephrol. 2012;2012:314251. doi: 10.1155/2012/314251. Epub 2012 May 24.
6
Animal models of acute renal failure.急性肾衰竭动物模型。
Pharmacol Rep. 2012;64(1):31-44. doi: 10.1016/s1734-1140(12)70728-4.
8
Bevacizumab and ovarian cancer.贝伐珠单抗与卵巢癌。
Curr Opin Obstet Gynecol. 2012 Feb;24(1):8-13. doi: 10.1097/GCO.0b013e32834daeed.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验